Scholarlink

<p>Laryngeal squamous cell carcinoma (LSCC) is one of the major malignant cancers worldwide. Emerging evidence has demonstrated that N6-methyladenosine (m6A) modification affects gene expression by regulating RNA metabolic processes, dynamically and reversibly regulated by its “writers”, “erasers” and “readers”. m6A modification plays an important role in the occurrence and development of various tumors. Recent studies have shown that m6A modifications are abnormally expressed in LSCC cells and tissues and participate in the malignant phenotypes of LSCC including cell proliferation, invasion, metastasis and chemotherapy resistance by mediating m6A regulators. This fundings may provide new directions for the molecular classification and targeted treatment of LSCC. In this review, we will focus on the molecular mechanism and potential clinical function of m6A modification in LSCC and emphasize its potential as a biomarker for the clinical diagnosis, prognosis, and treatment of LSCC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Emerging role of RNA m6A modifications in laryngeal squamous cell carcinoma: insights into tumorigenesis and therapeutic potential

  • 期刊论文

  • 发表日期：

    2025年8月14日

查看全文
  • Guotong Zheng,
  • Jing Bi,
  • Yangyan Yan,
  • Bo Yu,
  • Yong Fu

摘要

Laryngeal squamous cell carcinoma (LSCC) is one of the major malignant cancers worldwide. Emerging evidence has demonstrated that N6-methyladenosine (m6A) modification affects gene expression by regulating RNA metabolic processes, dynamically and reversibly regulated by its “writers”, “erasers” and “readers”. m6A modification plays an important role in the occurrence and development of various tumors. Recent studies have shown that m6A modifications are abnormally expressed in LSCC cells and tissues and participate in the malignant phenotypes of LSCC including cell proliferation, invasion, metastasis and chemotherapy resistance by mediating m6A regulators. This fundings may provide new directions for the molecular classification and targeted treatment of LSCC. In this review, we will focus on the molecular mechanism and potential clinical function of m6A modification in LSCC and emphasize its potential as a biomarker for the clinical diagnosis, prognosis, and treatment of LSCC.